Evolution of secondary prevention medications prescription after myocardial revascularisation: The ANCOR survey;Évolution de la prescription de prévention secondaire chez les coronariens après revascularisation: Enquête ANCOR (analyse nationale de la prise en charge de la maladie coronaire avant et après revascularisation)

Annales de Cardiologie et d'Angeiologie

Volumn 54, Issue 4, 2005, Pages 184-189

  Jullien, G ^a   Mosnier, M ^b   Danchin, N ^c  

^a Merck Lipha Santé ^*  (France)

^b Merck Lipha   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Coronary angioplasty; Coronary surgery; Secondary prevention

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; ANTIARRHYTHMIC AGENT;

ADULT; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOLOGY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY SURGERY; DIASTOLIC BLOOD PRESSURE; EVOLUTION; FEMALE; HEALTH SURVEY; HEART DISEASE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE PERIOD; PRESCRIPTION; PROPHYLAXIS; REVIEW; SMOKING; SYSTOLIC BLOOD PRESSURE; AGED; ARTICLE; CLINICAL PRACTICE; DRUG UTILIZATION; FRANCE; HEART INFARCTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; RECURRENT DISEASE; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NICORANDIL; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; PREOPERATIVE CARE; RECURRENCE;

EID: 23044513470     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2005.05.017     Document Type: Article

References (16)

1. N. Danchin, O. Grenier, J. Ferrìres, C. Cantet, and J.P. Cambou Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey Heart 88 2002 159 162
2. EUROASPIRE I and II group Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in 9 countries Lancet 357 2001 995 1001
3. R.A. Gibbons, J. Abrams, and K. Chatterjee ACC/AHA 2002 gudieline update for the management of patients with chronic stable angina. Summary article. A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (Committee on the management of patients with chronic stable angina) Circulation 107 2003 149 158
4. V. Snow, P. Barry, and S.D. Fihn Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians Ann. Intern. Med. 141 2004 562 567
5. P.W.J.C. Serruys, P. de Feyter, and C. Macaya Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial JAMA 287 2002 3215 3222
6. The IONA study group Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial Lancet 359 2002 1269 1275
7. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients BMJ 324 2002 71 86
8. The Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
9. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events Trial investigators N. Engl. J. Med. 335 1996 1001 1009
10. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N. Engl. J. Med. 339 1998 1349 1357
11. Heart Protection Study collaborative group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial Lancet 360 2002 7 22
12. The Heart Outcomes Prevention Evaluation Study investigators Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N. Engl. J. Med. 342 2000 145 153
13. The European trial on reduction of cardiac event with perindopril in stable coronary artery disease investigators Efficacy of perindopril on reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study) Lancet 362 2003 782 788
14. N. Danchin, G. Hanania, O. Grenier, L. Vaur, E. Amelineau, P. Gúret pour les investigateurs USIK 1995, Prevenir 1, Prevenir 2 et USIC 2000 Évolution du traitement de sortie apr̀s hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000 : donńs des ́tudes USIK 1995, Pŕvenir 1 et 2 et USIC 2000 Ann. Cardiol. Angeiol. (Paris) 52 2003 1 6
15. G. Hanania, J.P. Cambou, P. Gúret for the USIC 2000 investigators Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry Heart 90 2004 1404 1410
16. H.M. Colhoun, D. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atirvastatin Diabetes Study (CARDS):: multicentre randomised placebo-controlled trial Lancet 364 2005 685 696